Barclays PLC Grows Stake in Evolus, Inc. (NASDAQ:EOLS)

Barclays PLC increased its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 268.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 93,662 shares of the company's stock after acquiring an additional 68,213 shares during the quarter. Barclays PLC owned 0.15% of Evolus worth $1,518,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Jane Street Group LLC increased its position in Evolus by 47.0% in the 3rd quarter. Jane Street Group LLC now owns 91,899 shares of the company's stock valued at $1,489,000 after buying an additional 29,396 shares in the last quarter. Wellington Management Group LLP grew its stake in Evolus by 30.3% in the third quarter. Wellington Management Group LLP now owns 175,039 shares of the company's stock valued at $2,836,000 after acquiring an additional 40,715 shares during the period. Point72 Asset Management L.P. acquired a new stake in Evolus in the third quarter valued at approximately $132,000. Ikarian Capital LLC bought a new stake in shares of Evolus during the third quarter valued at approximately $4,184,000. Finally, Caligan Partners LP raised its position in shares of Evolus by 1.2% during the third quarter. Caligan Partners LP now owns 2,193,488 shares of the company's stock worth $35,535,000 after purchasing an additional 25,698 shares during the period. Institutional investors and hedge funds own 90.69% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on EOLS shares. Barclays lifted their price objective on shares of Evolus from $16.00 to $20.00 and gave the company an "overweight" rating in a report on Friday, September 13th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Evolus in a research note on Monday, September 16th. Needham & Company LLC restated a "buy" rating and issued a $22.00 target price on shares of Evolus in a report on Friday, September 13th. Finally, HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Evolus in a research report on Thursday, November 7th.

Evolus Stock Down 2.3 %

NASDAQ:EOLS traded down $0.26 on Friday, hitting $11.09. The stock had a trading volume of 471,960 shares, compared to its average volume of 588,460. Evolus, Inc. has a 1 year low of $9.80 and a 1 year high of $17.82. The firm's fifty day simple moving average is $13.35 and its two-hundred day simple moving average is $13.75. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The stock has a market cap of $702.23 million, a P/E ratio of -12.19 and a beta of 1.27.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.